RE: Nuvec comparable to Venetoclax and Gefitinib18 Oct 2023 14:12
Watched prezzo again last night.
Importantly, there will (in theory) be double the potential for newflow now.
Given that at 2.5mcap the company is almost priced for failure, there surely cannot be much more downside. Nanogenics needed money to take this project forward and N4 were there to buy in at a discount, taking advantage of their recent weak position and need for a cash injection. Nanogenics had lots of 'discussion' with potential partners but more data is required to move things forward (sounds familiar..!). Nigel seemed confident that future newsflow would result in a higher sp so we will see where the next few months takes N4P.